Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Sally Tran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background
Adverse outcomes of cirrhosis remain a top priority.
Aims
We examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S. cohort.
Methods
A retrospective study of a national sample of commercially insured patients with cirrhosis from Optum's de‐identified Clinformatics® Data Mart Database (CDM).
Results
A total of 628,743 cirrhosis cases were identified with 45% having NAFLD, 19.5% HCV, and 16.3% ALD. African Americans had the highest rate of decompensation (60.6%), while Asians had the highest rate of HCC (2.4%), both p < 0.001. African Americans more frequently had HCV (28.4%) while Hispanic/Latinos more frequently had NAFLD (49.2%, p < 0.001). Patients in the 2014–2021 cohort were significantly older (63.0 ± 12.8 vs. 57.0 ± 14.3), less frequently decompensated (54.5% vs. 58.3%) but more frequently had HCC (1.7% vs. 0.6%) and NAFLD (46.5% vs. 44.2%), all p < 0.001. The overall annual incidence of HCC was 0.76% (95% CI: 0.75–0.77) with a 5‐year cumulative incidence of 4.03% (95% CI: 3.98–4.09), with significant variation by sex, race/ethnicity, and cirrhosis aetiology. The overall median years of survival were 11.4 (95% CI: 11.3–11.5) with a 5‐year cumulative survival of 73.4% (95% CI: 73.3%–73.6%), also with significant disparities in similar subgroups (lowest in cryptogenic cirrhosis and worse in 2014–2021 vs. 2003–2013). The 2014–2021 period was independently associated with worse survival (aHR: 1.14, 95% CI: 1.08–1.20).
Conclusions
HCC incidence and survival vary by aetiology among patients with cirrhosis, with cryptogenic cirrhosis having the lowest survival and lower survival in the more recent time period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California, USA.
- Division of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
ORCID-Profile: YeeHui Yeo, Mindie H Nguyen
Förderung
- NCATS NIH HHS
Zitieren
APA
Tran, S., Zou, B., Lee, K., Kam, L., Yeo, Y., Henry, L., Cheung, R., & Nguyen, M. H. (2024). Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18024
Vancouver
Tran S, Zou B, Lee K, Kam L, Yeo Y, Henry L, et al. Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18024
BibTeX
@article{Tran2024,
author = {Tran, Sally and Zou, Biyao and Lee, KeeSeok and Kam, Leslie and Yeo, YeeHui and Henry, Linda and Cheung, Ramsey and Nguyen, Mindie H},
title = {Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18024}
}
EUVIMED